OXFORD BIODYNAMICS PLC

• ⚠

  Confirmation statement overdue

  Due 2026-05-09.

• ⚠

  Material uncertainty over going concern

  Material uncertainties exist that may cast significant doubt on the Group and Parent Company's ability to continue as a going concern, due to the need for additional funding beyond management's assessment period (to 31 December 2026) and uncertainties in revenue generation. Our opinion is not modified in respect of this matter.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +72.2%

  £636,000 → £1,095,000

• Cash

  -23.8%

  £1,827,000 → £1,392,000

• Net assets

  -74.4%

  £4,358,000 → £1,116,000

• Employees

  -19.6%

  51 → 41

• Operating profit

  +14.1%

  -£12,894,000 → -£11,074,000

• Profit before tax

  +4.5%

  -£11,956,000 → -£11,422,000

• Wages

  -9.5%

  £4,767,000 → £4,316,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. OXFORD BIODYNAMICS PLC 2016-10-13 → present
2. OXFORD BIODYNAMICS LIMITED 2007-04-25 → 2016-10-13

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Material uncertainties exist that may cast significant doubt on the Group and Parent Company's ability to continue as a going concern, due to the need for additional funding beyond management's assessment period (to 31 December 2026) and uncertainties in revenue generation. Our opinion is not modified in respect of this matter.”

Group structure

1. OXFORD BIODYNAMICS PLC · parent
   1. Oxford BioDynamics Inc. 100% · USA · Sales & Marketing
   2. Oxford BioDynamics (M) Sdn Bhd 100% · Malaysia · Diagnostic research
   3. Oxford BioDynamics Pte Ltd 100% · Singapore · Diagnostic research

Significant events

• “Fundraising generating £7.35m (before costs) (February 2025) to fund the ongoing business.”
• “Commenced development of breakthrough diagnostic test for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) (October 2025).”
• “Commenced third party discussions regarding the evaluation of and investment in EpiSwitch® Orion.”
• “Continued successive record months of PSE orders to November 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

7

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.